Infinite Load Articles

Roche announces details of its ‘pivotal’ huntingtin-lowering study

The GENERATION-HD1 trial will test whether RG6042 – formerly Ionis-HTTRx – slows the progression of Huntington's disease t’s a time of huge developments in the...

New £9.1m contract with a top 10 global pharmaceutical company

Specialist medical imaging services for a Phase III Huntington’s disease clinical trial, highlighting the value of IXICO’s data science expertise in neuroscience drug development. IXICO...

Predict the onset and course of Huntington’s disease

The origin of this incurable nervous disease lies in minute fibers formed by chains of the huntingtin protein MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE IN...

Study Suggests Potential Therapy for Huntington’s Disease

A new study published in the Proceedings of the National Academy of Sciences (PNAS) suggests that Huntington’s disease may take effect much earlier in life than...

PRIME designation granted by European Medicines Agency for RG6042 for treatment...

European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit...

Disappointing news from LEGATO-HD trial of laquinimod in Huntington’s disease

The LEGATO-HD trial of laquinimod did not slow progression of Huntington's disease. Here's the lowdown. The LEGATO-HD trial of laquinimod to slow progression of Huntington’s...

LATEST ARTICLES

Print Friendly, PDF & Email
0 Condivisioni